Potential endocrine disrupting chemicals (EDCs) are present in bottled water from various countries.
INTRODUCTION
The bottled water industry is growing globally. Between 1999 and 2012, the South African bottled water industry grew by 315% (Ronquest-Ross et al. ). The preference for bottled water can be attributed to perceived health benefits of bottled water or concerns regarding the quality of tap water, superior taste, lack of access to other suitable water sources, conven- Bisphenol-A (BPA), an EDC, is used for the manufacture of plastics, particularly polycarbonates and epoxy resins (Careghini et al. ) . Its endocrine disrupting activity is associated with cardiovascular disease, diabetes, obesity, and liver dysfunction. Fetal and early childhood exposure to BPA may cause secondary sexual developmental changes, neurobehavioral alterations and immune disorders (Erler & Novak ) . The EDC, 4-nonylphenol (4-NP) is used for the manufacture of surfactants and plastics (Inoue et al. ) . Exposure to 4-NP is a concern due to its toxic and estrogenic activity (Toyo'oka & Oshige ). Even though phthalates are not used in the manufacturing of polyethylene terephthalate (PET), several reports suggest that they may leach from PET bottles into the contents. Phthalates are associated with increased adiposity and insulin resistance, decreased levels of sex hormones, and other adverse effects on the human reproductive system. Infants and children are especially vulnerable to the toxic effects of phthalates (Sax ). A major exposure route for humans to BPA, 4-NP, and phthalates is through the ingestion of contaminated food (Careghini et al. ) .
EDCs are known to migrate from food packaging material into food (Muncke ) . The presence of EDCs in bottled water has been reported in various countries around the world. Bioassays revealed estrogenic activity in bottled water from Germany (Wagner & Oehlmann , ) and Italy (Pinto & Reali ) . BPA and 4-NP were detected in bottled water from Japan (Toyo'oka & Oshige ), Guangzhou, China (Li et al. ) , and Spain (Guart et al. a) . Diethyl phthalate (DEP), diisobutyl phthalate (DiBP), dibutyl phthalate (DBP), and di(2-ethylhexyl) phthalate (DEHP) were detected in PET bottled water from Canada (Cao ) . DBP, DiBP, and DEHP were also found in bottled water from Portugal (Santana et al. ) . DEHP was the most abundant phthalate in bottled water from Hungary (Keresztes et al. ). Wagner & Oehlmann () suggested three possible sources of estrogenic contamination of bottled water: the water source may be contaminated, contamination through the production process (e.g., disinfectants used to clean the filling system), or the migration of EDCs from the packaging material.
The growth of the bottled water industry in South Africa and the associated increase in use of plastic packaging necessitates the assessment of EDCs in locally bottled water. In this study, common South African brands of bottled water were screened for estrogenic activity and selected target chemicals.
The effect of storage temperature on estrogenic activity and chemical concentrations was investigated. A health risk assessment was conducted to determine the potential health risks associated with the consumption of the bottled water.
MATERIALS AND METHODS

Bottled water samples
Ten local brands of bottled water were purchased from supermarkets in Gauteng (South Africa). For each brand, eight 500 mL bottles (4 L) from the same batch were purchased. All the brands were in PET bottles and contained water from various sources, mineral composition and areas in South Africa and some of the brands were subjected to additional purification treatments before bottling. The composition of the bottled water samples appeared on the labels ( Millipore (Darmstadt, Germany).
Sample extraction
The extraction of EDCs from water samples was done using the solid phase extraction (SPE) procedure outlined by Oasis (Waters ). The pH of the water samples was adjusted to 3 before extraction. Oasis HLB SPE glass cartridges (5 cc/200 mg) were pre-conditioned with 5 mL 10% methanol in MtBE, 3 mL methanol, and 3 mL ddH 2 O. One-liter samples (2 × 500 mL bottles) were loaded onto each cartridge. The cartridges were washed with 3 mL 5% methanol in ddH 2 O and dried under vacuum. The samples were eluted from the cartridges using 6 mL 10% methanol in MtBE. Samples were extracted in duplicate. One sample was evaporated to dryness under a gentle nitrogen stream and reconstituted in 1 mL ethanol for bioassay analysis. Reconstituted samples were stored at À20 C. The second sample was split into two 3 mL fractions and evaporated. One fraction was derivatized and the other was reconstituted in 1 mL dicholoromethane for gas chromatography-mass spectrophotometry (GC-MS) analysis.
In vitro bioassays for estrogenic activity
Yeast estrogen screen (YES)
The YES assay was developed in the Genetics Department at 
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The detection limit of the yeast assay was calculated as the absorbance elicited by the solvent control plus three times the standard deviation. The E 2 standard curve was fitted (sigmoidal function, variable slope) using Graphpad Prism (version 4), and the estradiol equivalents (EEq) of water samples with three or more points above the detection limit were interpolated from the standard curve and corrected with the appropriate dilution factor for each sample.
T47D-KBluc reporter gene assay
The T47D-KBluc reporter gene assay is described in detail 
GC-MS analysis of target chemicals
Bottled water samples were analyzed for DEHA, DEHP, DBP, BPA, 4-NP, E 2 , E 1 , and EE 2 . E 2 , E 1 , and EE 2 were included as potential contaminants of source water, whereas the other target chemicals might be present in the source water or migrate from the packaging material into the water content. The fraction of the extract reconstituted in dicholoromethane was analyzed for DEHA, DEHP, and DBP using GC-MS. The second fraction was derivatized before it was analyzed for BPA, 4-NP, E 2 , E 1 , and EE 2 . The fraction that had to be derivatized was reconstituted in 100 μL 10% (v/v) methanol/MtBE containing α-cholestane as the internal standard at a concentration of 1 μg/mL. The reconstituted samples were then evaporated to dryness with nitrogen at 40 C.
100 μL of 2% methoxyamine in pyridine was added and the samples were derivatized for 30 minutes in an oven at 50 C. The vials were allowed to cool to room temperature and evaporated to dryness. The final derivatization was obtained by adding 100 μL of 0.05 M triethylamine in pyridine and 50 μL MSTFA to the vials, followed by heating for 1 hour at 80 C. The derivatives were allowed to cool to room temperature before being transferred to a GC vial with an insert. Stock solutions of the standards were prepared in methanol and the calibration dilutions were done in 10% (v/v) methanol/MTBE. The standards were processed in the same manner as the samples. The parameters for GC-MS analyses are given in Table 2 .
Human health risk assessment
The method described by the United States Environmental Protection Agency (USEPA) and the World Health Organization (WHO) (USEPA , ; WHO ) was used to conduct the human health risk assessment.
Human exposure to the identified substances on a daily basis was calculated using:
where ADD is the average daily dose (mg/kg/day), C m is the contaminant concentration (mg/kg), IR is the ingestion rate (kg/day), and BW is the body weight (kg).
For non-cancer risks, a hazard quotient (HQ) was calculated. The expected exposure to the agent is compared to an exposure that is assumed not to be associated with toxic effects. A hazard quotient less than 1 is considered to be safe for lifetime exposure:
where RfD is the reference dose reported by the USEPA ().
Exposures to carcinogens that last less than a lifetime (LADD) is calculated as:
where LADD is lifetime average daily dose (mg/kg/day), ED is exposure duration (years), and Lft is lifetime (years).
Carcinogenic risk was calculated as a function of oral potency factor (β) and dose:
The WHO acceptable risk level is 10 À5 (WHO ). 
RESULTS
In vitro bioassays for estrogenic activity
In the YES assay, no estrogenic activity or cytotoxicity was observed in any of the samples. However, in the T47D-KBluc assay, estrogenic activity was measured in two of the bottled water brands that were incubated at 20 C and in eight brands that were incubated at 40 C (Figure 1) .
EEq values ranged from 0.001 to 0.003 ng/L and no antiestrogenic activity was observed.
GC-MS analysis of target chemicals
The limit of detection (LOD) and limit of quantification (LOQ) for each target chemical is given in Table 3 . Due to the fact that the samples were concentrated a thousand times with the SPE procedure, target chemicals could be detected at concentrations a thousand times lower than the detection limits.
DEHA, DEHP, DBP, 4-NP, E 2 , E 1 , and EE 2 were below the detection limit in all the bottled water samples. BPA was Table 4 .
The hazard quotient for all the target chemicals was well below 1, indicating that these chemicals are unlikely to pose a human health risk from drinking 2 L of bottled water every day. The carcinogenic risk was also well below the WHO acceptable risk of 10 À5 .
DISCUSSION
Estrogenic activity and selected EDCs were found in bottled water samples from South Africa at both temperatures. The use of bottled water is pronounced in hot climates.
The demand for bottled water is met by widespread transport and storage facilities that are not often climate 
